

Appln. No. 10/070,954
Amd. dated May 27, 2008


Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A sulfonamide compound according to formula I



with its geometrical isomers, in an optically active form as enantiomers, diastereomers, as well as in the form of racemates, as well as pharmaceutically acceptable salts thereof, wherein

Ar¹ and Ar² are independently from each other substituted or unsubstituted aryl or heteroaryl groups with the proviso that Ar² is not 1,3-phenylene or 1,4-phenylene,

X is O or S;

R¹ is hydrogen or a C₁-C₆-alkyl group, or R¹ forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar¹;

n is an integer from 0 to 5;

Y within formula I is a substituted or unsubstituted piperidino moiety, whereby one nitrogen atom within said

Appln. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008


piperidino moiety forms a bond with the sulfonyl group of formula I thus providing a sulfonamide,

with the proviso that if Ar¹ is 4-chlorophenyl, then X is O, R¹ is H, Ar² is thienyl, and Y is not para-substituted by 2-hydroxyethyl,

with the further proviso that if Ar¹ is phenyl, then X is O, R¹ is H, Ar² is thienyl, and Y is not substituted in its β position by a benzo [5,6] cyclohepta [1,2b] pyridine or a benzo [5,6] cyclohept [3,4]ene [1,2b] pyridine;

with the final proviso that if X is oxygen, then Y shall not be substituted by a group (C=O)N(R,R') at the α-position of the sulfonamide nitrogen.

2. (Currently Amended) A composition comprising a sulfonamide compound according to formula I



with its geometrical isomers, in an optically active form as enantiomers, dia-stereomers, as well as in the form of racemates, as well as pharmaceutically acceptable salts thereof, wherein

Ar¹ and Ar² are ~~are independently~~ substituted or unsubstituted aryl or heteroaryl groups with the proviso that neither Ar¹ nor Ar² is neither 1,3-phenylene or 1,4-phenylene

Appn. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

and Ar¹ is not phenylene or quinazoline that is substituted by nitro, hydroxyl, or 3,4-dichlorophenyl amino,

X is O or S;

R¹ is hydrogen or a C₁-C₆-alkyl group, or R¹ forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar¹;


n is an integer from 0 to 5;

Y within formula I is a piperidino group whereby one nitrogen atom within said piperidino group forms a bond with the sulfonyl group of formula I thus providing a sulfonamide;

with the proviso that if Y is substituted at the β-position of the piperidino-nitrogen by a benzo[5, 6]cyclohepta[1, 2b]pyridine, or a benzo[5, 6]cyclohept [3, 4]ene [1, 2b]pyridine, while Ar² is thienyl, X is oxygen, R¹ is hydrogen and n is 1, Ar¹ shall not be a phenyl group;

and a pharmaceutically acceptable carrier with the final proviso that if X is oxygen, Y shall not be substituted by a group (C=O)N(R,R') at the α-position of the sulfonamide nitrogen.

3. (Previously Presented) A sulfonamide compound according to claim 1 or a composition according to claim 2, wherein Y is a piperidino group of the formula



whereby, L^1 and L^2 are independently selected from each other from the group consisting of H, substituted or unsubstituted C_1-C_6 -alkyl, substituted or unsubstituted C_2-C_6 -alkenyl, substituted or unsubstituted C_2-C_6 -alkynyl, substituted or unsubstituted cyclic C_4-C_8 -alkyl optionally containing 1-3 heteroatoms and optionally fused with aryl or heteroaryl; or L^1 and L^2 are independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aryl- C_1-C_6 -alkyl, heteroaryl- C_1-C_6 -alkyl, $-C(O)-OR^3$, $-C(O)-R^3$, $-C(O)-NR^{3'}R^3$, $-NR^{3'}R^3$, $-NR^{3'}C(O)R^3$, $-NR^{3'}C(O)NR^{3'}R^3$, $-(SO)R^3$, $-(SO_2)R^3$, $-NHSO_2R^3$, and $-SO_2NR^{3'}R^3$,

with R^3 and $R^{3'}$ being substituents independently selected from the group consisting of H, substituted or unsubstituted C_1-C_6 -alkyl, substituted or unsubstituted C_2-C_6 -alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl- C_1-C_6 -alkyl and substituted or unsubstituted heteroaryl- C_1-C_6 -alkyl;

Appln. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

 said aryl or heteroaryl groups being optionally substituted C₁-C₆-alkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, amino, acylamino, aminocarbonyl, C₁-C₆-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl, sulfoxy, and C₁-C₆-thioalkoxy, and

 R⁶ is selected from the group consisting of hydrogen, substituted or unsubstituted C₁-C₆-alkyl, substituted or unsubstituted C₁-C₆-alkoxy, OH, halogen, nitro, cyano, sulfonyl and oxo (=O), and

 n' is an integer from 0 to 4.

Claim 4. (Cancelled)

5. (Previously Presented) A sulfonamide compound according to claim 1, wherein Ar¹ and Ar² are independently selected from the group consisting of phenyl, thienyl, furyl, pyridyl, and optionally substituted by C₁-C₆-alkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, amino, acylamino, aminocarbonyl, C₁-C₆-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl and C₁-C₆-thioalkoxy.

6. (Previously Presented) A sulfonamide compound according to claim 5, wherein Ar¹ is an unsubstituted or substituted phenyl.


Appn. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

7. (Previously Presented) A sulfonamide compound according to claim 5, wherein Ar² is an unsubstituted or substituted thienyl or furanyl group.

8. (Previously Presented) A sulfonamide compound according to claim 1, wherein Ar¹ is selected from the group consisting of a 4-chlorophenyl, nitrophenyl, hydroxyphenyl, alkoxy phenyl, pyridyl, 3,4,-dihydroxyphenyl, thioxo-dihydropyridine or its tautomer and pyrazole and X is O, R¹ is hydrogen, n is 1, Ar² is thienyl or furanyl.

9. (Currently Amended) A sulfonamide compound according to claim 8, wherein Y is



(R⁶)_{n'} is selected from the group consisting of hydrogen, substituted or unsubstituted C₁-C₆ alkyl, substituted or unsubstituted C₁-C₆ alkoxy, OH, halogen, nitro, cyano, sulfonyl, and oxo; n' is an integer of from 0 to 4; and wherein L¹ and L² are independently selected from each other from the group consisting of H, substituted or unsubstituted C₁-C₆- alkyl, substituted or unsubstituted C₂-C₆ alkenyl; or L¹ and L² are independently selected from the group

Appn. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cyclic C₄-C₈ alkyl optionally containing 1-3 heteroatoms and optionally fused with aryl or heteroaryl, aryl-C₁-C₄ alkyl, heteroaryl-C₁-C₄ alkyl, -C(O)-OR³, -C(O)-R³, -C(O)-NR³R³, -NR³R³; -NR³'C(O)R³', -NR³'-C(O)NR³R³, -(SO)R³, -(SO₂)R³, -NHSO₂R³, and -SO₂NR³R³;

with R³ and R³' being substituents independently selected from the group consisting of H, substituted or unsubstituted C₁-C₄ alkyl, substituted or unsubstituted C₂-C₆ alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl-C₁-C₄-alkyl, substituted or unsubstituted heteroaryl-C₁-C₆-alkyl;


said aryl or heteroaryl groups being optionally substituted with a member selected from the group consisting of C₁-C₆-alkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, amino, acylamino, aminocarbonyl, C₁-C₆-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl, sulfoxy, and C₁-C₆-thioalkoxy.

10. (Previously Presented) A sulfonamide compound according to claim 9, wherein R⁶ is H, L² is H, L¹ is a 5-membered cyclic group containing 3 heteroatoms or L¹ is -C(O)-R³, or -NHR³;

Appln. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

wherein Y is



n' is an integer of from 0 to 4;

with R^3 being a substituent selected from the group comprising or consisting of C_1-C_4 -alkyl, aryl, heteroaryl, $aryl-C_1-C_4$ -alkyl and heteroaryl- C_1-C_6 -alkyl;

said aryl or heteroaryl groups being optionally substituted by halogen, hydroxy, nitro, or sulfonyl.

11. (Currently Amended) A sulfonamide compound according to claim 1, selected from the group consisting of:

4-chloro-N-[5-[4-(3-trifluoromethanesulfonyl-phenylamino)-piperidine-1-sulfonyl]-thiophen-2-ylmethyl]-benzamide;

4-chloro-N-[(5-[4-(4-fluorobenzoyl)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-[(4-hydroxy-4-phenylpiperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide;

N-[(5-[(4-benzoypiperidin-1-yl)sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide;

Appn. No. 10/070,954

Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007

and Advisory Actions of April 10, 2008 and May 19, 2008

4-chloro-N-[(5-{ [4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]sulfonyl }thien-2-yl)methyl]benzamide;

N-{5-[(4-benzylpiperidin-1-yl)sulfonyl]thien-2-yl }methyl)-4-chlorobenzamide;

4-chloro-N-[(5-{ [4-(2,4-difluorobenzoyl)piperidin-1-yl]sulfonyl }thien-2-yl)methyl]benzamide;

tert-butyl 1-[(5-{ [(4-chlorobenzoyl)amino]methyl }thien-2-yl)sulfonyl]piperidin-4-ylcarbamate;

4-chloro-N-{ [5-(piperidin-1-ylsulfonyl)thien-2-yl]methyl}benzamide;

4-chloro-N-{ [5-({3-hydroxy-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N-[(5-{ [4-(benzyloxy)piperidin-1-yl]sulfonyl }thien-2-yl)methyl]-4-chlorobenzamide;

~~N-(4-chlorophenyl)-2-(5-{ [4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]sulfonyl }thien-2-yl)benzamide;~~

4-chloro-N-{5-[(4-hydroxypiperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

N-{5-[(4-benzyl-4-hydroxypiperidin-1-yl)sulfonyl]thien-2-yl)methyl)-4-chlorobenzamide;

Appln. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

N- { [5- ({4- [(2-tert-butyl-1H-indol-5-
yl)amino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl } -4-
chlorobenzamide;

4-chloro-N- { [5- ({4- [(phenylacetyl)amino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl } benzamide;

N- [(5- { [4- (2H-1,2,3-benzotriazol-2-yl)piperidin-1-
yl}sulfonyl)thien-2-yl]methyl] -4-chlorobenzamide;

4-chloro-N- [(5- { [4- (4-chlorobenzoyl)piperidin-1-
yl}sulfonyl)thien-2-yl]methyl] benzamide;

4-chloro-N- ({5- [(4-phenoxy)piperidin-1-
yl}sulfonyl)thien-2-yl]methyl] benzamide;

N- { [5- ({4- [benzyl (methyl)amino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl } -4-chlorobenzamide;

4-chloro-N- { [5- ({4- [3- (2,4-dichlorophenyl)-1H-
pyrazol-5-yl]piperidin-1-yl}sulfonyl)thien-2-
yl]methyl } benzamide;

4-chloro-N- [(5- { [4- (5-thien-2-yl-1H-pyrazol-3-
yl)piperidin-1-yl}sulfonyl)thien-2-yl]methyl] benzamide;

4-chloro-N- [(5- { [4- (2,3,4,5,6-
pentamethylbenzoyl)piperidin-1-yl}sulfonyl)thien-2-
yl]methyl] benzamide;

4-chloro-N- { [5- ({4- [5- (4-methoxyphenyl)-1H-pyrazol-
3-yl]piperidin-1-yl}sulfonyl)thien-2-yl]methyl } benzamide;

Appln. No. 10/070,954

Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007

and Advisory Actions of April 10, 2008 and May 19, 2008

N- ({5- [(4-anilinopiperidin-1-yl)sulfonyl]thien-2-yl}methyl)-4-chlorobenzamide;

4-chloro-N- [(5-{[4-(2-phenylethyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N- [(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

~~2-(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)-N-(4-chlorophenyl)benzamide;~~

2-{1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-2H-1,2,3-benzotriazole-5-carboxylic acid;

~~4-chloro-N-[(5-{[4-(5-chloro-1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;~~

methyl 1-{1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-5-carboxylate;

methyl 1-{1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-6-carboxylate;

methyl 2-{1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-2H-1,2,3-benzotriazole-5-carboxylate;

4-chloro-N- [(5-{[4-(6-chloro-1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

4-chloro-N-[5-({4-[5-(trifluoromethyl)-1H-1,2,3-benzotriazol-1-yl]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N-[5-{[4-(7-aza-1H-benzimidazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

1-{1-[5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl]sulfonyl}piperidin-4-yl}-1H-1,2,3-benzotriazole-5-carboxylic acid;

1-{1-[5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl]sulfonyl}piperidin-4-yl}-1H-1,2,3-benzotriazole-6-carboxylic acid;

N-[5-{[4-(2-amino-9H-purin-9-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[5-{[4-(9H-purin-9-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[5-{[4-(6-amino-9H-purin-9-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-({5-[(4-{6-nitro-1H-benzimidazol-1-yl}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-chloro-N-({5-[(4-{5-nitro-1H-benzimidazol-1-yl}piperidin-1-yl)sulfonyl]thien-2-yl)methyl}benzamide;

4-chloro-N-[5-{[4-(2H-1,2,3-triazol-2-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

N- [(5- { [4- (1H-benzimidazol-1-yl)piperidin-1-
yl] sulfonyl}thien-2-yl)methyl] -4-chlorobenzamide;
4-chloro-N- { [5- ({4- [3-propylanilino]piperidin-1-
yl] sulfonyl}thien-2-yl)methyl]benzamide;
4-chloro-N- { [5- ({4- [3-
(trifluoromethyl)anilino]piperidin-1-yl} sulfonyl)thien-2-
yl] methyl]benzamide;
4-chloro-N- { [5- ({4- [3-
(dimethylamino)anilino]piperidin-1-yl} sulfonyl)thien-2-
yl] methyl]benzamide;
methyl 3- ({1- [(5- { [(4-chlorobenzoyl)amino]-
methyl}thien-2-yl] sulfonyl}piperidin-4-yl}amino)-benzoate;
4-chloro-N- { [5- ({4- [3-
(methylsulfanyl)anilino]piperidin-1-yl} sulfonyl)thien-2-
yl] methyl]benzamide;
4-chloro-N- ({5- [(4- {3-nitroanilino}piperidin-1-
yl) sulfonyl}thien-2-yl)methyl]benzamide;
4-chloro-N- [(5- { [4- (2-methoxyanilino)piperidin-1-
yl] sulfonyl}thien-2-yl)methyl]benzamide;
3- ({1- [(5- { [(4-chlorobenzoyl)amino]methyl}thien-2-
yl] sulfonyl}piperidin-4-yl}amino)benzamide;
4-chloro-N- { [5- ({4- [2-
(trifluoromethyl)anilino]piperidin-1-yl} sulfonyl)thien-2-
yl] methyl]benzamide;

Appn. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

4-chloro-N-((5-[(4-(2-nitro-4-
[(trifluoromethyl)sulfonyl]anilino)piperidin-1-
yl)sulfonyl]thien-2-yl)methyl)benzamide;
4-chloro-N-[(5-{[4-(4-chloroanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
4-chloro-N-{[5-({4-[4-
(trifluoromethyl)anilino)piperidin-1-yl}sulfonyl)thien-2-
yl)methyl}benzamide;
4-chloro-N-((5-[(4-(4-
[(trifluoromethyl)sulfonyl]anilino)piperidin-1-
yl)sulfonyl]thien-2-yl)methyl)benzamide;
4-chloro-N-((5-[(4-(2-nitroanilino)piperidin-1-
yl)sulfonyl]thien-2-yl)methyl)benzamide;
N-{[5-({4-[4-(aminocarbonyl)anilino)piperidin-1-
yl}sulfonyl)thien-2-yl)methyl}-4-chlorobenzamide;
4-chloro-N-{[5-({4-[4-(1,3-dithiolan-2-
yl)anilino)piperidin-1-yl}sulfonyl)thien-2-
yl)methyl}benzamide;
N-[(5-{[4-(3-chloroanilino)piperidin-1-
yl}sulfonyl)thien-2-yl)methyl]-3-nitrobenzamide;
4-chloro-N-[(5-{[4-(3-chloroanilino)piperidin-1-
yl}sulfonyl)thien-2-yl)methyl]benzamide;
4-chloro-N-[(5-{[4-(3-methoxyanilino)piperidin-1-
yl}sulfonyl)thien-2-yl)methyl]benzamide;

Appn. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

4-chloro-N-[{5-[{4-[3-(methylsulfonyl)anilino]piperidin-1-yl}sulfonyl]thien-2-yl}methyl]benzamide;

N-[{5-[(4-{3-[amino(imino)methyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl}methyl]-4-chlorobenzamide;

4-chloro-N-[{5-[(4-{3-[(2-hydroxyethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]thien-2-yl}methyl]benzamide;

N-[(5-{[4-(2-aminoanilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(2-hydroxyanilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(4-hydroxyanilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl]benzamide;

4-chloro-N-[{5-[(4-{3-[(trifluoromethyl)sulfanyl]anilino}piperidin-1-yl}sulfonyl]thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(3-toluidino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-[(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}piperidin-1-yl}sulfonyl]thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

4-chloro-N-[5-({4-[3-(1,3-oxazol-5-yl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N-[(5-{[4-(3-tert-butylanilino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(2-propylanilino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]benzamide;

4-chloro-N-[5-({4-[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

4-chloro-N-[(5-{[4-(2,3-dihydro-1H-inden-5-ylamino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(4-propylanilino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]benzamide;

4-chloro-N-[(5-{[4-(3-nitropyridin-2-yl)amino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]benzamide;

N-{[5-({4-[(3-aminopyridin-2-yl)amino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-4-chlorobenzamide;

N-[(5-{[4-([1,1'-biphenyl]-3-ylamino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]-4-chlorobenzamide;

N-[(5-{[4-(3-benzylanilino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

4-chloro-N-[5-(4-[4-(morpholin-4-ylsulfonyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl]methyl}benzamide;

4-chloro-N-[5-[4-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}piperidin-1-yl]sulfonyl]thien-2-yl]methyl}benzamide;

4-chloro-N-[5-[4-(3-cyclohexyl-4-hydroxyanilino)piperidin-1-yl]sulfonyl]thien-2-yl]methyl}benzamide;

N-[5-[4-{3-[(butylamino)sulfonyl]anilino}piperidin-1-yl]sulfonyl]thien-2-yl]methyl)-4-chlorobenzamide;

4-chloro-N-[5-[4-(3-ethylanilino)piperidin-1-yl]sulfonyl]thien-2-yl]methyl}benzamide;

4-chloro-N-[5-[4-(5,6,7,8-tetrahydronaphthalen-1-ylamino)piperidin-1-yl]sulfonyl]thien-2-yl]methyl}benzamide;

N-[5-[4-[3-(aminosulfonyl)anilino]piperidin-1-yl]sulfonyl]thien-2-yl]methyl}-4-chlorobenzamide;

4-chloro-N-[5-[4-(quinolin-5-ylamino)piperidin-1-yl]sulfonyl]thien-2-yl]methyl}benzamide;

4-chloro-N-[5-[4-(quinolin-8-ylamino)piperidin-1-yl]sulfonyl]thien-2-yl]methyl}benzamide;

4-Chloro-N-[5-[4-(3-propylphenoxy)piperidin-1-yl]sulfonyl]thien-2-yl]methyl}benzamide;

Appln. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

4-nitro-N-({5-[{4-{3-[
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-
yl]sulfonyl]thien-2-yl)methyl}benzamide;
N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl]sulfonyl]thien-2-yl)methyl]-3-nitrobenzamide;
N-[(5-{[4-(2,4-difluorobenzoyl)piperidin-1-
yl]sulfonyl]thien-2-yl)methyl]-4-nitrobenzamide;
N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl]sulfonyl]thien-2-yl)methyl]-4-nitrobenzamide;
3-nitro-N-[(5-{[4-(3-methoxyanilino)piperidin-1-
yl]sulfonyl]thien-2-yl)methyl]benzamide;
3-nitro-N-{{5-[{4-[3-
(trifluoromethyl)anilino}piperidin-1-yl]sulfonyl]thien-2-
yl)methyl}benzamide;
N-{{5-[{4-[3-(dimethylamino)anilino}piperidin-1-
yl]sulfonyl]thien-2-yl)methyl}-3-nitrobenzamide;
3-nitro-N-{{5-[{4-[3-
(methylsulfonyl)anilino}piperidin-1-yl]sulfonyl]thien-2-
yl)methyl}benzamide;
3-nitro-N-{{5-[{4-[3-
(methylsulfanyl)anilino}piperidin-1-yl]sulfonyl]thien-2-
yl)methyl}benzamide;
N-{{5-[{4-[3-(aminosulfonyl)anilino}piperidin-1-
yl]sulfonyl]thien-2-yl)methyl}-3-nitrobenzamide;

Appln. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

methyl 3-[{1-[{5-[({3-nitrobenzoyl}amino)methyl]-thien-2-yl}sulfonyl]-piperidin-4-yl]amino}benzoate;

N-{[5-[{4-[3-(aminocarbonyl)anilino]piperidin-1-yl}sulfonyl]thien-2-yl]methyl}-3-nitrobenzamide;

3-nitro-N-({5-[{4-[3-nitroanilino]piperidin-1-yl}sulfonyl]thien-2-yl)methyl)benzamide;

3-nitro-N-[(5-{[4-(2-methoxyanilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl]benzamide;

3-nitro-N-{[5-[{4-[2-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl]thien-2-yl)methyl}benzamide;

3-nitro-N-({5-[{4-[2-nitroanilino]piperidin-1-yl}sulfonyl]thien-2-yl)methyl}benzamide;

N-[(5-{[4-(4-chloroanilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-{[5-[{4-[4-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl]thien-2-yl)methyl}benzamide;

3-nitro-N-({5-[{4-[{4-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl}sulfonyl]thien-2-yl)methyl}benzamide;

N-{[5-[{4-[4-(aminocarbonyl)anilino]piperidin-1-yl}sulfonyl]thien-2-yl)methyl}-3-nitrobenzamide;

Appln. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

N- [(5- { [4- (3-propylanilino)piperidin-1-
yl] sulfonyl} thien-2-yl)methyl] -3-nitrobenzamide;

N- [(5- { [4- (3-chloroanilino)piperidin-1-
yl] sulfonyl} thien-2-yl)methyl] -4-nitrobenzamide;

4-nitro-N- [(5- { [4- (3-methoxyanilino)piperidin-1-
yl] sulfonyl} thien-2-yl)methyl] benzamide;

4-nitro-N- { [5- ({4- [3-
(trifluoromethyl)anilino] piperidin-1-yl} sulfonyl) thien-2-
yl] methyl} benzamide;

N- { [5- ({4- [3- (dimethylamino)anilino] piperidin-1-
yl} sulfonyl) thien-2-yl] methyl} -4-nitrobenzamide;

4-nitro-N- [(5- { [4- (3-propylanilino)piperidin-1-
yl] sulfonyl} thien-2-yl)methyl] benzamide;

4-nitro-N- { [5- ({4- [3-
(methylsulfonyl)anilino] piperidin-1-yl} sulfonyl) thien-2-
yl] methyl} benzamide;

4-nitro-N- { [5- ({4- [3-
(methylsulfanyl)anilino] piperidin-1-yl} sulfonyl) thien-2-
yl] methyl} benzamide;

N- { [5- ({4- [3- (aminosulfonyl)anilino] piperidin-1-
yl} sulfonyl) thien-2-yl] methyl} -4-nitrobenzamide;

methyl 3- { [1- ({5- [(4-nitrobenzoyl)amino] methyl} -
thien-2-yl} sulfonyl) piperidin-4-yl] amino} benzoate;

Appln. No. 10/070,954
Amd. dated May 27, 2008
Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

3-[1-({5-[({4-nitrobenzoyl}amino)methyl]thien-2-yl}sulfonyl)piperidin-4-yl]amino}benzamide;

4-nitro-N-({5-[({3-nitroanilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl}benzamide;

4-nitro-N-[(5-{[4-(2-methoxyanilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl}benzamide;

4-nitro-N-{[5-({4-[2-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl]thien-2-yl)methyl}benzamide;

4-nitro-N-({5-[({2-nitroanilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl}benzamide;

N-[(5-{[4-(4-chloroanilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl]-4-nitrobenzamide;

4-nitro-N-{[5-({4-[4-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl]thien-2-yl)methyl}benzamide;

4-nitro-N-({5-[({4-[{trifluoromethyl}sulfonyl]anilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl}benzamide;

N-{[5-({4-[4-(aminocarbonyl)anilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl}-4-nitrobenzamide;

N-{[5-({4-[4-(1,3-dithiolan-2-yl)anilino)piperidin-1-yl}sulfonyl]thien-2-yl)methyl}-4-nitrobenzamide;

Appln. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

N- ({ 5- [(4- { 3- [amino (imino) methyl] anilino} piperidin-1-yl) sulfonyl] thien-2-yl} methyl) -3-nitrobenzamide;

N- ({ 5- [(4- { 3- [(2- hydroxyethyl) sulfonyl] anilino} piperidin-1-yl) sulfonyl] thien-2-yl} methyl) -3-nitrobenzamide;

N- ({ 5- [(4-anilinopiperidin-1-yl) sulfonyl] thien-2-yl} methyl) -3-nitrobenzamide;

N- ({ 5- [(4- { 3- [(2- hydroxyethyl) sulfonyl] anilino} piperidin-1-yl) sulfonyl] thien-2-yl} methyl) -4-nitrobenzamide;

N- ({ 5- [(4-anilinopiperidin-1-yl) sulfonyl] thien-2-yl} methyl) -4-nitrobenzamide;

N- ({ 5- [(4- { 3- [amino (imino) methyl] anilino} piperidin-1-yl) sulfonyl] thien-2-yl} methyl) -4-nitrobenzamide;

3-nitro-N- [(5- { [4- ({ 3-nitropyridin-2-yl} amino) piperidin-1-yl) sulfonyl] thien-2-yl} methyl] benzamide;

N- { [5- { [4- [(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl) amino] piperidin-1-yl} sulfonyl] thien-2-yl} methyl] -3-nitrobenzamide;

N- [(5- { [4- (2,3-dihydro-1H-inden-5-ylamino) piperidin-1-yl] sulfonyl] thien-2-yl} methyl] -3-nitrobenzamide;

3-nitro-N- [(5- { [4- (2-propylanilino) piperidin-1-yl] sulfonyl] thien-2-yl} methyl] benzamide;

Appn. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

3-nitro-N-[(5-{[4-(4-propylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-[(5-{[4-(3-tert-butylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-{[5-({4-[3-(1,3-oxazol-5-yl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

3-nitro-N-[(5-{[4-(2-phenylethyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

N-({5-[(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl)-3-nitrobenzamide;

N-[(5-{[4-([1,1'-biphenyl]-3-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

N-[(5-{[4-(3-benzylanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-{[5-({4-[3-(morpholin-4-ylsulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

3-nitro-N-[(5-{[4-(3-propylphenoxy)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-nitro-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appn. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

N- { [5- { [4- [(3- aminopyridin-2- yl) aminol piperidin-1- yl} sulfonyl) thien-2- yl] methyl} -4-nitrobenzamide;

4-nitro-N- [(5- { [4- (3-nitropyridin-2- yl) amino) piperidin-1- yl] sulfonyl} thien-2- yl) methyl] benzamide;

N- [(5- { [4- (2,3-dihydro-1H-inden-5-ylamino) piperidin-1- yl] sulfonyl} thien-2- yl) methyl] -4-nitrobenzamide;

4-nitro-N- [(5- { [4- (2-propylanilino) piperidin-1- yl] sulfonyl} thien-2- yl) methyl] benzamide;

4-nitro-N- [(5- { [4- (4-propylanilino) piperidin-1- yl] sulfonyl} thien-2- yl) methyl] benzamide;

N- [(5- { [4- (3-tert-butyylanilino) piperidin-1- yl] sulfonyl} thien-2- yl) methyl] -4-nitrobenzamide;

4-nitro-N- { [5- { [4- [3- (1,3-oxazol-5- yl) anilino] piperidin-1- yl] sulfonyl} thien-2- yl] methyl} benzamide;

4-nitro-N- [(5- { [4- (2-phenylethyl) piperidin-1- yl] sulfonyl} thien-2- yl) methyl] benzamide;

N- { [5- [(4- { [3-chloro-5- (trifluoromethyl) pyridin-2- yl] amino) piperidin-1- yl] sulfonyl} thien-2- yl] methyl} -4- nitrobenzamide;

N- [(5- { [4- ([1,1'-biphenyl]-3-ylamino) piperidin-1- yl] sulfonyl} thien-2- yl) methyl] -4-nitrobenzamide;

N- [(5- { [4- (3-benzylanilino) piperidin-1- yl] sulfonyl} thien-2- yl) methyl] -4-nitrobenzamide;

Appn. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

4-nitro-N-{[5-({4-[3-(morpholin-4-yl)sulfonyl]anilino)piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;

N-[(5-{[4-(2-aminoanilino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]benzamide;

N-{[5-({4-[(3-aminopyridin-2-yl)amino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-3-nitrobenzamide;

N-({5-[(4-{2-nitro-4-[(trifluoromethyl)sulfonyl]anilino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-3-methoxybenzamide;

3-nitro-N-({5-[(4-{[4-(trifluoromethyl)pyrimidin-2-yl]amino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

N-[(5-{[4-(3-cyclohexyl-4-hydroxyanilino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]-3-nitrobenzamide;

N-({5-[(4-{3-[(butylamino)sulfonyl]anilino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-3-nitrobenzamide;

N-[(5-{[4-(3-ethylanilino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]-3-nitrobenzamide;

3-nitro-N-[(5-{[4-(5,6,7,8-tetrahydronaphthalen-1-ylamino)piperidin-1-yl}sulfonyl)thien-2-yl)methyl]benzamide;

Appn. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

4-nitro-N-[(5-[4-(3-propylphenoxy)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]benzamide;

N-[(5-[4-(2,4-difluorobenzoyl)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]-3-nitrobenzamide;

N-[(5-[4-(2,4-difluorobenzoyl)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]-3-methoxybenzamide;

2-Hydroxy-N-({5-[(4-{3-[trifluoromethyl}sulfonyl]anilino)piperidin-1-yl]sulfonyl)thien-2-yl)methyl}benzamide;

N-[(5-[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]-3-methoxybenzamide;

N-[(5-[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]-2-hydroxybenzamide;

N-{[5-({4-[4-(1,3-dithiolan-2-yl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-3-nitrobenzamide;

3-methoxy-N-[(5-{[4-(3-methoxyanilino)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]benzamide;

3-methoxy-N-{[5-({4-[3-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}benzamide;

N-{[5-({4-[3-(dimethylamino)anilino]piperidin-1-yl}sulfonyl)thien-2-yl)methyl}-3-methoxybenzamide;

3-methoxy-N-[(5-{[4-(3-propylanilino)piperidin-1-yl]sulfonyl)thien-2-yl)methyl]benzamide;

Appn. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

3-methoxy-N-[5-(4-[3-[methylsulfonyl]anilino]piperidin-1-yl)sulfonyl]thien-2-yl]methyl}benzamide;

3-methoxy-N-[5-(4-[3-[methylsulfanyl]anilino]piperidin-1-yl)sulfonyl]thien-2-yl]methyl}benzamide;

N-[5-(4-[3-(aminosulfonyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl}-3-methoxybenzamide;

methyl 3-((1-((5-((3-methoxybenzoyl)amino)-methyl)thien-2-yl)sulfonyl)piperidin-4-yl)amino)-benzoate;

N-[5-(4-[3-(aminocarbonyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl}-3-methoxybenzamide;

3-methoxy-N-[(5-((4-(2-methoxyanilino)piperidin-1-yl)sulfonyl)thien-2-yl)methyl]benzamide;

N-((5-((4-(3-nitroanilino)piperidin-1-yl)sulfonyl)thien-2-yl)methyl)-3-methoxybenzamide;

3-methoxy-N-[5-(4-[2-(trifluoromethyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl]methyl}benzamide;

N-((5-((4-(2-nitroanilino)piperidin-1-yl)sulfonyl)thien-2-yl)methyl)-3-methoxybenzamide;

N-[5-(4-[4-(aminocarbonyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl}-3-methoxybenzamide;

Appln. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

N-{[5-({4-[4-(1,3-dithiolan-2-yl)anilino]piperidin-1-yl} sulfonyl)thien-2-yl]methyl}-3-methoxybenzamide;

N-[(5-{[4-(3-chloroanilino)piperidin-1-yl] sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

N-[(5-{[4-(4-chloroanilino)piperidin-1-yl] sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N-({5-[(4-{4-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl} sulfonyl)thien-2-yl]methyl)benzamide;

N-({5-[(4-{3-[amino(imino)methyl]anilino}piperidin-1-yl} sulfonyl)thien-2-yl]methyl}-3-methoxybenzamide;

N-({5-[(4-{3-[(2-hydroxyethyl)sulfonyl]anilino}piperidin-1-yl} sulfonyl)thien-2-yl]methyl}-3-methoxybenzamide;

3-methoxy-N-({5-[(4-{3-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl} sulfonyl)thien-2-yl]methyl)benzamide;

N-({5-[(4-anilinopiperidin-1-yl)sulfonyl]thien-2-yl}methyl)-3-methoxybenzamide;

3-methoxy-N-({5-[(4-{3-[(trifluoromethyl)sulfanyl]anilino}piperidin-1-yl} sulfonyl)thien-2-yl]methyl)benzamide;

N-[(5-{[4-(4-hydroxyanilino)piperidin-1-yl] sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

Appln. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

3-nitro-N-[(5-[(4-{3-[
[(trifluoromethyl)sulfanyl]anilino}piperidin-1-
yl)sulfonyl]thien-2-yl)methyl]benzamide;
4-nitro-N-[(5-[(4-{3-[
[(trifluoromethyl)sulfanyl]anilino}piperidin-1-
yl)sulfonyl]thien-2-yl)methyl]benzamide;
N-[(5-{[4-(2-hydroxyanilino)piperidin-1-
yl]sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;
3-methoxy-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-
1-yl]sulfonyl]thien-2-yl)methyl]benzamide;
N-{[5-([4-[(3-aminopyridin-2-yl)amino]piperidin-1-
yl]sulfonyl)thien-2-yl)methyl}-3-methoxybenzamide;
N-[(5-{[4-((3-nitropyridin-2-yl)amino)piperidin-1-
yl]sulfonyl)thien-2-yl)methyl]-3-methoxybenzamide;
N-{[5-([4-[(2,2-dioxido-1,3-dihydro-2-benzothien-5-
yl)amino]piperidin-1-yl]sulfonyl)thien-2-yl)methyl}-3-
methoxybenzamide;
N-[(5-{[4-(2,3-dihydro-1H-inden-5-ylamino)piperidin-
1-yl]sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;
3-methoxy-N-[(5-{[4-(2-propylanilino)piperidin-1-
yl]sulfonyl]thien-2-yl)methyl]benzamide;
3-methoxy-N-[(5-{[4-(4-propylanilino)piperidin-1-
yl]sulfonyl]thien-2-yl)methyl]benzamide;

Appln. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

N- [(5- { [4- (3-tert-butylanilino)piperidin-1-
yl] sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

N- ({5- [(4- { [3-chloro-5-(trifluoromethyl)pyridin-2-
yl] amino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl)-3-
methoxybenzamide;

3-methoxy-N- { [5- ({4- [3- (1,3-oxazol-5-
yl) anilino]piperidin-1-yl}sulfonyl)thien-2-
yl] methyl}benzamide;

N- [(5- { [4- ([1,1'-biphenyl]-3-ylamino)piperidin-1-
yl] sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N- [(5- { [4- (3-propylphenoxy)piperidin-1-
yl] sulfonyl}thien-2-yl)methyl]benzamide;

3-methoxy-N- { [5- ({4- [3- (morpholin-4-
ylsulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2-
yl] methyl}benzamide;

3-methoxy-N- [(5- { [4- (2-phenylethyl)piperidin-1-
yl] sulfonyl}thien-2-yl)methyl]benzamide;

N- [(5- { [4- (3-benzylanilino)piperidin-1-
yl] sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

3-methoxy-N- ({5- [(4- { [4- (trifluoromethyl)pyrimidin-
2-yl] amino}piperidin-1-yl)sulfonyl]thien-2-
yl)methyl}benzamide;

N- [(5- { [4- (3-cyclohexyl-4-hydroxyanilino)piperidin-
1-yl] sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;

Appn. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

N- ({ 5- [(4- { 3-
[(butylamino)sulfonyl]anilino)piperidin-1-yl)sulfonyl]thien-2-
yl}methyl)-3-methoxybenzamide;
N- [(5- { [4- (3-ethylanilino)piperidin-1-
yl)sulfonyl]thien-2-yl)methyl]-3-methoxybenzamide;
3-methoxy-N- [(5- { [4- (5,6,7,8-tetrahydronaphthalen-1-
ylamino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]benzamide;
N- [(5- { [4- (1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl)sulfonyl]thien-2-yl)methyl]-5-nitro-1H-pyrazole-3-
carboxamide;
N- [(5- { [4- (1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl)sulfonyl]thien-2-yl)methyl]-2-oxo-1,2-dihdropyridine-3-
carboxamide;
N- [(5- { [4- (1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl)sulfonyl]thien-2-yl)methyl]-2-thioxo-1,2-dihdropyridine-3-
carboxamide;
N- [(5- { [4- (1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl)sulfonyl]thien-2-yl)methyl]-3,4-dihydroxybenzamide;
N- [(5- { [4- (1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl)sulfonyl]thien-2-yl)methyl]pyridine-2-carboxamide;
N- [(5- { [4- (hexyloxy)piperidin-1-yl)sulfonyl]thien-2-
yl)methyl]-3-methoxybenzamide;
N- ({ 5- [(4-heptanoylpiperidin-1-yl)sulfonyl]thien-2-
yl}methyl)-3-methoxybenzamide;

Appn. No. 10/070,954
Amd. dated May 27, 2008
Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

4-chloro-N-[(5-[4-(3-propylanilino)piperidin-1-yl]sulfonyl)-2-furyl)methyl]benzamide;

4-chloro-N-[(5-[4-(3-chloroanilino)piperidin-1-yl]sulfonyl)-2-furyl)methyl]benzamide;

4-chloro-N-[(5-[4-(3-methoxyanilino)piperidin-1-yl]sulfonyl)-2-furyl)methyl]benzamide;

4-chloro-N-{[5-(4-[3-(trifluoromethyl)anilino)piperidin-1-yl]sulfonyl)-2-furyl)methyl}benzamide;

4-chloro-N-{[5-(4-[3-(dimethylamino)anilino)piperidin-1-yl]sulfonyl)-2-furyl)methyl}benzamide;

4-chloro-N-{[5-(4-[3-(methylsulfonyl)anilino)piperidin-1-yl]sulfonyl)-2-furyl)methyl}benzamide;

4-chloro-N-{[5-(4-[3-(methylsulfanyl)anilino)piperidin-1-yl]sulfonyl)-2-furyl)methyl}benzamide;

N-{[5-(4-[3-(aminosulfonyl)anilino)piperidin-1-yl]sulfonyl)-2-furyl)methyl}-4-chlorobenzamide;

methyl 3-((1-[(5-[(4-chlorobenzoyl)amino]methyl)-2-furyl)sulfonyl)piperidin-4-yl)amino)benzoate;

3-((1-[(5-[(4-chlorobenzoyl)amino]methyl)-2-furyl)sulfonyl)piperidin-4-yl)amino)benzamide;

Appln. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

4-chloro-N-({5-[{4-{3-nitroanilino}piperidin-1-yl}sulfonyl]-2-furyl}methyl)benzamide;

4-chloro-N-[{5-[{4-(2-methoxyanilino)piperidin-1-yl}sulfonyl]-2-furyl}methyl]benzamide;

4-chloro-N-{[5-({4-[2-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)-2-furyl]methyl}benzamide;

4-chloro-N-({5-[{4-{2-nitroanilino}piperidin-1-yl}sulfonyl]-2-furyl}methyl)benzamide;

4-chloro-N-[{5-[{4-(4-chloroanilino)piperidin-1-yl}sulfonyl]-2-furyl}methyl]benzamide;

4-chloro-N-{[5-({4-[4-(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)-2-furyl]methyl}benzamide;

4-chloro-N-({5-[{4-[{4-[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl}sulfonyl]-2-furyl}methyl)benzamide;

N-{[5-({4-[4-(aminocarbonyl)anilino]piperidin-1-yl}sulfonyl)-2-furyl]methyl}-4-chlorobenzamide;

4-chloro-N-{[5-({4-[4-(1,3-dithiolan-2-yl)anilino]piperidin-1-yl}sulfonyl)-2-furyl]methyl}benzamide;

N-{[5-[(4-{3-[amino(imino)methyl]anilino}piperidin-1-yl)sulfonyl]-2-furyl]methyl}-4-chlorobenzamide;

Appln. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

4-chloro-N-({5-[{4-{3-[{(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl]sulfonyl]-2-furyl}methyl)benzamide;
N-({5-[{4-anilinopiperidin-1-yl]sulfonyl]-2-furyl}methyl)-4-chlorobenzamide; and
4-nitro-N-({5-[{4-{3-[{(trifluoromethyl)sulfanyl]anilino}piperidin-1-yl]sulfonyl]-2-furyl}methyl)benzamide.

12. (Previously Presented) A sulfonamide compound according to claim 11, which is selected from the group consisting of:

4-chloro-N-[(5-[{4-(2,4-difluorobenzoyl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;
N-({5-[{4-anilinopiperidin-1-yl]sulfonyl}thien-2-yl}methyl)-4-chlorobenzamide;
N-[(5-[{4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;
N-[(5-[{4-(1H-benzimidazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;
4-chloro-N-{{5-[{4-[3-propylanilino]piperidin-1-yl]sulfonyl}thien-2-yl)methyl}benzamide;
4-chloro-N-[(5-[{4-(4-chloroanilino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

Appn. No. 10/070,954
Amd. dated May 27, 2008
Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

4-chloro-N-([5-[4-[3-[2-hydroxyethyl]sulfonyl]anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl)benzamide;
N-([5-([4-[3-(aminosulfonyl)anilino]piperidin-1-yl)sulfonyl]thien-2-yl)methyl)-4-chlorobenzamide;
4-nitro-N-([5-([4-(3-methoxyanilino)piperidin-1-yl)sulfonyl]thien-2-yl)methyl)benzamide;
methyl 3-[[1-([5-([4-nitrobenzoyl]amino)methyl]thien-2-yl)sulfonyl)piperidin-4-yl]amino]benzoate;
N-[(5-([4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl)sulfonyl]thien-2-yl)methyl]-2-hydroxybenzamide; and
N-([5-([4-{2-nitroanilino}piperidin-1-yl)sulfonyl]thien-2-yl)methyl)-3-methoxybenzamide.


Claims 13-19. (Cancelled)

20. (Previously Presented) A pharmaceutical composition containing at least one sulfonamide compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

21. (Currently Amended) Process for the preparation of a sulfonamide compound according to claim 1, comprising reacting a sulfonyl chloride V


Appn. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008



V

with an amine VIII



VIII

whereby n is an integer of from 0 to 5, $n'-(\text{R}^6)_{n'}$ is an integer of from 0 to 4, $\text{n}-\text{R}_6$ is selected from the group consisting of hydrogen, substituted or unsubstituted $\text{C}_1\text{-}\text{C}_6$ alkyl, substituted or unsubstituted $\text{C}_1\text{-}\text{C}_6$ alkoxy, OH, halogen, nitro, cyano, sulfonyl and oxo;

L^1 and L^2 are independently selected from each other from the group consisting of hydrogen, substituted or unsubstituted $\text{C}_1\text{-}\text{C}_6$ alkyl, substituted or unsubstituted $\text{C}_1\text{-}\text{C}_6$ alkenyl, substituted or unsubstituted $\text{C}_1\text{-}\text{C}_6$ alkynyl, substituted or unsubstituted cyclic $\text{C}_1\text{-}\text{C}_6\text{C}_4\text{-}\text{C}_8$ alkyl optionally containing 1-3 heteroatoms and optionally fused with aryl or heteroaryl; or L^1 and L^2 are independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aryl- $\text{C}_1\text{-}\text{C}_6$ alkyl- Heteroaryl- heteroaryl- $\text{C}_1\text{-}\text{C}_6$ alkyl, substituted or unsubstituted cyclic $\text{C}_4\text{-}\text{C}_8$ alkyl optionally containing 1-3


Appn. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

heteroatoms and optionally fused with aryl or heteroaryl, -
 $C(O)R^3$, $-C(O)OR^3$, $-C(O)-NR^3'R^3$, $-NR^3'R^3$, $-NR^3'C(O)R^3$, $-$
 $NR^3'C(O)NR^3R^3$ $-(SO)R^3$, $(SO_2)R^3$, $NHSO_2R^3$ and $SO_2NR^3'R^3$;
with R^3 and R^3' being substituents independently selected from the group consisting of hydrogen, substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted $\underline{C_1C_2}-C_6$ alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl- C_1-C_6 alkyl and substituted or unsubstituted heteroaryl- C_1-C_6 alkyl,

said aryl or heteroaryl groups being optionally substituted C_1-C_6 alkyl, C_1-C_6 alkoxy, $\underline{C_1C_2}-C_6$ alkenyl, $\underline{C_1C_2}-C_6$ alkynyl, amino, acylamino, aminocarbonyl, $\underline{C_1C_2}-C_6$ alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl, sulfoxy and C_1-C_6 thioalkoxy.

22. (Previously Presented) A process according to claim 21, wherein said sulfonyl chloride V is obtained by
a) coupling an amine of formula II:




with an acyl chloride of formula III:




Appn. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

to provide an amide of formula IV:



b) sulfonating the amide of formula IV to provide a sulfonyl chloride V



Claims 23-26. (Cancelled)

27. (Previously Presented) The sulfonamide compound according to claim 1 wherein n is an integer of from 1 to 3.

28. (Previously Presented) The sulfonamide compound according to claim 27 wherein n is 1.

29. (Previously Presented) The composition according to claim 2 wherein n is an integer of from 1 to 3.

30. (Previously Presented) The composition according to claim 29 wherein n is 1.

31. (Previously Presented) The composition according to claim 3 wherein n is 1 or 2.

Appn. No. 10/070,954
Amd. dated May 27, 2008

Reply to Office Action of December 26, 2007
and Advisory Actions of April 10, 2008 and May 19, 2008

Claims 32-34. (Cancelled)

35. (Previously Presented) The sulfonamide compound according to claim 5 wherein the C₁-C₆ alkyl group is trihalomethyl.

36. (Previously Presented) The sulfonamide compound according to claim 9 wherein L¹ is a triazole ring which is fused with an aryl ring.

Claims 37-41. (Cancelled)